{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:09:29Z","timestamp":1791227369364,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1470,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1742-481x.2011.00849.x","type":"journal-article","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T21:31:43Z","timestamp":1314826303000},"page":"567-577","source":"Crossref","is-referenced-by-count":26,"title":["Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus"],"prefix":"10.1111","volume":"8","author":[{"given":"Andreas","family":"Ambrosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Haefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Jude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Lobmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,23]]},"reference":[{"issue":"Suppl 1","key":"10.1111\/j.1742-481X.2011.00849.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/dmrr.833","article-title":"The diabetic foot: grand overview, epidemiology and pathogenesis.","volume":"24","author":"Boulten","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1096-9136(199809)15:9<760::AID-DIA672>3.0.CO;2-I","article-title":"Problem of amputations in patients with newly diagnosed diabetes mellitus.","volume":"15","author":"New","year":"1998","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.12968\/jowc.1996.5.2.52","article-title":"Management of neuropathic ulceration.","volume":"5","author":"McGill","year":"1996","journal-title":"J Wound Care"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2796.1993.tb01003.x","article-title":"Long-term prognosis for diabetic patients with foot ulcers.","volume":"233","author":"Apelquist","year":"1993","journal-title":"J Intern Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1464-5491.1985.tb00588.x","article-title":"Hospital admissions of diabetic patients. Information from hospital activity analysis.","volume":"2","author":"Williams","year":"1985","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.7547\/87507315-87-7-321","article-title":"Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetics versus nondiabetic adults.","volume":"87","author":"Armstrong","year":"1997","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/(SICI)1096-9136(199611)13:11<967::AID-DIA266>3.0.CO;2-K","article-title":"Increased mortality associated with diabetic foot ulcer.","volume":"11","author":"Boyko","year":"1996","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB8|cit8","first-page":"551","article-title":"The diabetes control and complications trial study. Implications for the diabetic foot.","volume":"33","author":"DeFronzo","year":"1994","journal-title":"J Foot Ankle Surg"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1055\/s-2001-14102","article-title":"Costs of type 2 diabetes in Germany. Results of the CODE-2 study.","volume":"126","author":"Liebl","year":"2001","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s00125-008-1089-6","article-title":"Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study.","volume":"5","author":"Prompers","year":"2008","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1056\/NEJM199409293311307","article-title":"Assessment and management of foot disease in patients with diabetes.","volume":"331","author":"Caputo","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7547\/87507315-87-8-360","article-title":"Therapeutic footwear helps protect the diabetic foot.","volume":"87","author":"Mueller","year":"1997","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB13|cit13","volume-title":"Internationaler konsensus \u00fcber den diabetischen fuss.","author":"Spraul","year":"1999"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB14|cit14","first-page":"485","volume-title":"Diabetes in America. NIH Publications No 95-1468.","author":"Boyko","year":"1995"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1464-5491.1994.tb00250.x","article-title":"Infections and diabetes. Mechanisms and prospects of prevention.","volume":"11","author":"Pozzilli","year":"1995","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.15.2.256","article-title":"Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes.","volume":"15","author":"Marhoffer","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1749-6632.2002.tb03012.x","article-title":"The lymphocyte as a cellular model to study insights into the pathophysiology of diabetes and its complications.","volume":"958","author":"Balasubrmanyam","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0895-7061(99)00129-6","article-title":"Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus.","volume":"12","author":"Orie","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB19|cit19","first-page":"187","article-title":"Impaired immune responses in diabetes mellitus. Analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections.","volume":"18","author":"Moutschen","year":"1992","journal-title":"Diabetes Metab"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB20|cit20","first-page":"77","article-title":"Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus.","volume":"19","author":"Bouter","year":"1992","journal-title":"Diabetes Res"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB21|cit21","first-page":"479","article-title":"Attachment of staphylococci to various synthetic polymers.","volume":"256","author":"Ludwicka","year":"1984","journal-title":"Zentralbl Bakteriol Hyg"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1021\/bi00093a021","article-title":"Identification and biochemical characterization of the ligand binding domain of collagen adhesin of Staphylococcus aureus.","volume":"32","author":"Patti","year":"1993","journal-title":"Biochemistry"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1099\/13500872-142-8-2153","article-title":"A low-fibronectin-binding mutant of Staphylococcus aureus 879R4S has Tn918 inserted into its single fnb gene.","volume":"142","author":"Greene","year":"1996","journal-title":"Microbiology"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00005-010-0079-9","article-title":"Slime production by Staphylococcus aureus and Staphylococcus epidermidis strains isolated from patients with diabetic foot ulcers.","volume":"58","author":"Podbielska","year":"2010","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00002480-199440020-00018","article-title":"Immune regulation of bacterial biofilm graft infection.","volume":"40","author":"Bergamini","year":"1994","journal-title":"ASAIO J"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0003-9969(99)00014-X","article-title":"The effect of extracellular polysaccharides from Streptococcus mutans on the bactericidal activity of human neutrophils.","volume":"44","author":"Steinberg","year":"1999","journal-title":"Arch Oral Biol"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1099\/00222615-41-5-359","article-title":"Interaction between human polymorphonuclear leucocytes and bacteria released from in-vitro bacterial biofilm models.","volume":"41","author":"Yasuda","year":"1994","journal-title":"J Med Microbiol"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1524-475X.2007.00283.x","article-title":"Why chronic wounds will not heal: a novel hypothesis.","volume":"16","author":"Bjarnsholt","year":"2008","journal-title":"Wound Repair Regen"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/JCM.36.9.2530-2534.1998","article-title":"Chronic prosthetic hip infection caused by a small-colony variant of Escherichia coli.","volume":"36","author":"Roggenkamp","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/jb.179.15.4706-4712.1997","article-title":"A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly.","volume":"179","author":"Eiff","year":"1997","journal-title":"J Bacteriol"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB31|cit31","first-page":"44","article-title":"Staphylococcus aureus small colony variants. Formation and clinical impact.","volume":"115","author":"Eiff","year":"2000","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-2008-1054234","article-title":"Development of gentamicin-resistant small colony variants of S. aureus after implantation of gentamicin chains in osteomyelitis as a possible cause of recurrence.","volume":"136","author":"Eiff","year":"1998","journal-title":"Z Orthop Ihre Grenzgeb"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/514706","article-title":"Small colony variants in staphylococcal infections. Diagnostic and therapeutic implications.","volume":"27","author":"Proctor","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.2337\/dc08-1010","article-title":"Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers.","volume":"31","author":"Sotto","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/37.10.1095","article-title":"Surface associated protein from Staphylococcus aureus stimulates osteoclasteogenesis. Possible role in S. aureus-induced bone pathology.","volume":"37","author":"Meghji","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00125-010-1672-5","article-title":"Skin and soft tissue infections in hospitalized patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost.","volume":"53","author":"Lipsky","year":"2010","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0953-6205(03)00107-9","article-title":"Infections in diabetic foot ulcers.","volume":"14","author":"Candel Gonzales","year":"2003","journal-title":"Eur J Intern Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB38|cit38","first-page":"317","article-title":"Diabetes foot infections: prevalence and antibiotic sensitivity of the causative organisms.","volume":"27","author":"Martinez-Gomez Dde","year":"2009","journal-title":"Enferm Infect Microbiol Clin"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diabet.2008.02.005","article-title":"Risk factors and healing impact of multidrug resistant bacteria in diabetic foot ulcers.","volume":"34","author":"Richard","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00125-010-1893-7","article-title":"Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose.","volume":"54","author":"Ramakant","year":"2011","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2337\/dc06-0116","article-title":"A clinico-microbiological study of diabetic foot ulcers in an Indian teriary care hospital.","volume":"29","author":"Gadepalli","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00774-09","article-title":"Characterization of a new metallo-\u00df-lactames gene, blaNDM-1, and a novel erythromycin estsrease gene carrier on a unique genetic structure in Klebsiella pneumiae sequence typ 14 from India.","volume":"53","author":"Yong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/cir273","article-title":"Country-to-country transfer of patients and the risk of multi-resistant bacterial infection.","volume":"53","author":"Rogers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diabet.2008.02.005","article-title":"Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers.","volume":"34","author":"Richard","year":"2008","journal-title":"Diabet Metab"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1464-5491.1999.00132.x","article-title":"Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic.","volume":"16","author":"Tentolouris","year":"1999","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.diabres.2008.01.009","article-title":"Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials.","volume":"80","author":"Vardakas","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1464-5491.2004.01237.x","article-title":"Diabetic foot ulcer and multidrug resistant organisms: risk factor and impact.","volume":"21","author":"Hartemann-Heurtier","year":"2004","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s00125-008-1131-8","article-title":"Outcome of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement.","volume":"51","author":"Aragon-Sanchez","year":"2008","journal-title":"Diabetologia"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB49|cit49","first-page":"302","article-title":"Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome.","volume":"48","author":"Fejfarova","year":"2002","journal-title":"Vnitr Lek"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdiacomp.2007.04.004","article-title":"Epidemiology of diabetic foot problems and predictive factors for limb loss.","volume":"22","author":"Nather","year":"2008","journal-title":"J Diabetes Complicat"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jac\/dkl393","article-title":"Bactericidial agents in the treatment of MRSA infections - the potential role of daptomycin.","volume":"58","author":"French","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin-structure infections caused by Gram-positive bacteria: the FAST 2 study.","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","article-title":"Oritavancin pharmacokinetics in healthy subjects and patients with complicated skin and skin-structure infections and bacteremia.","volume":"53","author":"Rubino","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.patbio.2007.07.003","article-title":"In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.","volume":"55","author":"Sooto","year":"2007","journal-title":"Pathol Biol"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in the treatment of skin and skin structure infections. Results of a double-blind phase 3 comparison study with vancomycin-aztreonam.","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecycline monotherapy compared to vancomycin plus aztreonam in patients with complicated skin and skin-structure infections: results from a phase 3 randomised double-blind trial.","volume":"9","author":"Sacchdanand","year":"2005","journal-title":"Int J Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.","volume":"26","author":"Postier","year":"2004","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"Tigecycline 300 and 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.","volume":"41","author":"Grosse","year":"2005","journal-title":"Clin Inf Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/jac\/dkp483","article-title":"In vitro bactericidial activity of ceftobiprole against hospital and community associated methicillin-resistant Staphyloccous aureus.","volume":"65","author":"Borbone","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trail comparing ceftobriprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/AAC.47.1.371-374.2003","article-title":"Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome.","volume":"47","author":"Legat","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jac\/dkh531","article-title":"Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.","volume":"55","author":"Lipsky","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jac\/dkn149","article-title":"Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.","volume":"62","author":"Tillotson","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jac\/44.2.263","article-title":"Treatment of hospitalized patients with complicated Gram-positive skin and skin-structure infections: two randomized, multicentre studies of qionopristin\/dafopristin versus cefazolin, oxacillin or vancomycin.","volume":"44","author":"Nichols","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/383472","article-title":"Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens.","volume":"38","author":"Carpenter","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/13543780902967624","article-title":"Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.","volume":"18","author":"Falagas","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkp230","article-title":"High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.","volume":"64","author":"Schintler","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkh143","article-title":"Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.","volume":"53","author":"Streit","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10096-009-0808-3","article-title":"Clinical characteristics and outcomes of diabetic patients with Staphyloccous aureus bacteremia and endocarditis.","volume":"28","author":"Kanafani","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetic and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00469-10","article-title":"Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance study (CANWARD 2008).","volume":"54","author":"Zhanel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dki109","article-title":"Comparative evaluation of tigeycline and vancomycin with and without rifampicin in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model.","volume":"55","author":"Yin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1128\/AAC.00286-06","article-title":"In vitro activities of Dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections.","volume":"50","author":"Goldstein","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.","volume":"15","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin structure infections caused by Gram-positive organisms.","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1128\/AAC.00642-09","article-title":"In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.","volume":"54","author":"Fernandez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin-structure infections caused by Gram-positive bacteria.","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/AAC.00129-09","article-title":"Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates.","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00096-06","article-title":"Phase II, randomized double-blind multicenter study comparing the safety and phamacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.","volume":"50","author":"Weems","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.01316-09","article-title":"Detection and characterization of hetergenous vancomycin-intermediate Staphyloccous aureus isolates in Canada: results from the Canadian nosocomial infection surveillance program 1995-2006","volume":"54","author":"Adam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1128\/AAC.00616-09","article-title":"Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine US Medical centers from 2002-2006.","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkm271","article-title":"Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections.","volume":"60","author":"Stein","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/380449","article-title":"Linezolid diabetic foot infections study group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin\/amoxicillin-clavulanate","volume":"38","author":"Lipsky","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.00206-07","article-title":"Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus.","volume":"51","author":"Cenizal","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.diagmicrobio.2007.10.016","article-title":"Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.","volume":"60","author":"Mendes","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/00365540701466231","article-title":"Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin-resistant and methicillin-sensitive S. aureus from the Oslo area.","volume":"39","author":"Jorgen","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/AAC.48.3.1007-1011.2004","article-title":"In vitro activity of daptomycin against Gram-positive European clinica isolates with defined resistant determinants.","volume":"48","author":"Fluit","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"Daptomycin 98-01 and 99-01 investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1179\/joc.2010.22.1.13","article-title":"Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States Medical Centers from 2004 through 2008.","volume":"22","author":"Putnam","year":"2010","journal-title":"J Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1179\/joc.2008.20.1.53","article-title":"Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model.","volume":"20","author":"Kandemir","year":"2008","journal-title":"J Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infections.","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","article-title":"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.","volume":"13","author":"Schneider","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1128\/AAC.01383-08","article-title":"Multicenter, randomized study on the efficacy and safety of intravenous iclaprim in complicated skin and skin-structure infections.","volume":"53","author":"Krievins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-481X.2011.00849.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1128\/IAI.73.8.5229-5232.2005","article-title":"Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.","volume":"73","author":"Domanski","year":"2005","journal-title":"Infect Immun"}],"container-title":["International Wound Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-481X.2011.00849.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-481X.2011.00849.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T21:37:47Z","timestamp":1612733867000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/j.1742-481X.2011.00849.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,23]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-481x.2011.00849.x","relation":{},"ISSN":["1742-4801"],"issn-type":[{"value":"1742-4801","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,23]]}}}